ULTRAVIST 300 IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Ultravist 300 In Plastic Container, and when can generic versions of Ultravist 300 In Plastic Container launch?

Ultravist 300 In Plastic Container is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in ULTRAVIST 300 IN PLASTIC CONTAINER is iopromide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the iopromide profile page.

Summary for ULTRAVIST 300 IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	86
Clinical Trials:	11
Patent Applications:	2,584
DailyMed Link:	ULTRAVIST 300 IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for ULTRAVIST 300 IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bayer	Phase 4
Guerbet/Liebel-Flarsheim	Phase 4
Duke Clinical Research Institute	Phase 4

See all ULTRAVIST 300 IN PLASTIC CONTAINER clinical trials

Pharmacology for ULTRAVIST 300 IN PLASTIC CONTAINER

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

US Patents and Regulatory Information for ULTRAVIST 300 IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	ULTRAVIST 300 IN PLASTIC CONTAINER	iopromide	INJECTABLE;INJECTION	020220-005	Nov 18, 2008		DISCN	Yes	No

International Patents for ULTRAVIST 300 IN PLASTIC CONTAINER

See the table below for patents covering ULTRAVIST 300 IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	2909439
Yugoslavia	61780
Spain	491254
South Africa	8001350
Australia	529565

ULTRAVIST 300 IN PLASTIC CONTAINER Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for ULTRAVIST 300 in Plastic Containers

Introduction

ULTRAVIST 300, a nonionic, sterile, and pyrogen-free aqueous solution of iopromide, is a widely used contrast agent in medical imaging. This article delves into the market dynamics and financial trajectory of ULTRAVIST 300, particularly when packaged in plastic containers.

Market Overview of Contrast Media

The global contrast media market, which includes products like ULTRAVIST 300, is experiencing significant growth driven by the increasing demand for advanced diagnostic imaging and the rising prevalence of chronic diseases such as cancer and cardiovascular conditions[4].

Key Indications and Uses of ULTRAVIST 300

ULTRAVIST 300 is used for contrast enhancement in various medical imaging procedures, including computerized tomography (CT), arteriography, venography, intravenous urography, and the visualization of body cavities like arthrography. It is not intended for intrathecal use[2].

Market Size and Growth

The Canada contrast media market, which is a subset of the global market, was estimated at USD 187.60 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2030, reaching USD 300.15 million by 2030. The X-ray/CT segment, where ULTRAVIST 300 is predominantly used, held the largest share of 64.4% in 2023[4].

Competitive Landscape

The contrast media market is highly competitive, with key players such as Bayer AG, GE HealthCare, Guerbet, Lantheus Holdings, Inc., Bracco, and Voyageur Pharmaceuticals, Ltd. These companies are engaged in various strategies including new product development, collaborations, acquisitions, and mergers to meet the unmet needs of their customers[4].

Packaging and Its Impact

The packaging of pharmaceutical products, including contrast media like ULTRAVIST 300, is a critical aspect of the market. Primary packaging, which comes into direct contact with the product, must ensure the stability, sterility, and quality of the contrast agent. For injectable medications like ULTRAVIST 300, materials such as glass and plastics are commonly used. Plastic containers, in particular, offer flexibility and are often preferred for their ease of use and sterility[3].

Financial Trajectory

The financial trajectory of ULTRAVIST 300 is closely tied to the overall growth of the contrast media market. With the market projected to grow significantly over the next few years, the demand for ULTRAVIST 300 and its associated packaging is expected to increase. Here are some key financial indicators:

• Revenue Growth: The global pharmaceutical packaging market, which includes packaging for contrast media, was estimated at US$ 139.40 billion in 2023 and is projected to grow to US$ 387.50 billion by 2034, at a CAGR of 9.74% from 2024 to 2034[3].
• Segment Growth: The injectables segment, where ULTRAVIST 300 falls, is anticipated to grow at the fastest CAGR in the pharmaceutical packaging market during the forecast period. This growth is driven by the increasing demand for sterile injectable medications and the need for high-quality packaging materials[3].

Regional Market Dynamics

North America, particularly the U.S. and Canada, dominates the pharmaceutical packaging market, including the segment for contrast media. The presence of large pharmaceutical sectors and continuous research and development activities in these regions drive the demand for advanced diagnostic imaging and, consequently, for contrast agents like ULTRAVIST 300[3].

Regulatory Environment

The pharmaceutical packaging industry, including the packaging of contrast media, is strictly regulated by national and international governments and agencies. Ensuring patient safety is paramount, and packaging must comply with strict regulations to prevent counterfeiting and maintain product quality and sterility[3].

Challenges and Opportunities

Challenges

• Regulatory Compliance: Adhering to strict regulatory requirements can be challenging for manufacturers.
• Counterfeiting: Ensuring the authenticity of products is a significant concern in the pharmaceutical packaging industry.
• Material Selection: Choosing the right packaging materials that ensure stability and sterility while being cost-effective is crucial.

Opportunities

• Growing Demand: The increasing demand for advanced diagnostic imaging and the rise in chronic diseases present significant growth opportunities.
• Innovative Packaging: Developing unique and high-quality packaging solutions can help companies differentiate themselves in a competitive market.
• Collaborations and Acquisitions: Strategic collaborations and acquisitions can enhance market presence and product offerings[3][4].

Key Takeaways

• Market Growth: The contrast media market, including ULTRAVIST 300, is expected to grow significantly driven by the demand for advanced diagnostic imaging.
• Packaging Importance: Primary packaging, particularly in plastic containers, plays a crucial role in ensuring the quality and sterility of ULTRAVIST 300.
• Regulatory Compliance: Strict adherence to regulatory requirements is essential for maintaining product integrity and patient safety.
• Competitive Landscape: The market is highly competitive, with key players engaging in various strategies to enhance their market position.

FAQs

What is ULTRAVIST 300 used for?

ULTRAVIST 300 is used for contrast enhancement in medical imaging procedures such as CT scans, arteriography, venography, intravenous urography, and the visualization of body cavities like arthrography[2].

What are the key components of ULTRAVIST 300?

ULTRAVIST 300 is a nonionic, sterile, and pyrogen-free aqueous solution of iopromide, available in various strengths including 62.3%[1].

How is ULTRAVIST 300 packaged?

ULTRAVIST 300 is typically packaged in injectable form, often in plastic or glass containers to ensure stability and sterility[3].

What drives the demand for ULTRAVIST 300?

The demand for ULTRAVIST 300 is driven by the increasing need for advanced diagnostic imaging and the rising prevalence of chronic diseases such as cancer and cardiovascular conditions[4].

Who are the key players in the contrast media market?

Key players in the contrast media market include Bayer AG, GE HealthCare, Guerbet, Lantheus Holdings, Inc., Bracco, and Voyageur Pharmaceuticals, Ltd[4].

Sources

1. Pharmacompass: Ultravist 300 | Drug Information, Uses, Side Effects, Chemistry[1]
2. Bayer: SELECT THE REQUIRED INFORMATION - Bayer[2]
3. Towards Healthcare: Pharmaceutical Packaging Market Size, Trends and Statistics[3]
4. Grand View Research: Canada Contrast Media Market Size & Share Report, 2030[4]